NCT03613142 is a NA clinical trial of Double tract anatomosis in Gastric Cancer, sponsored by Peking University Cancer Hospital & Institute.

Who is sponsoring NCT03613142?

NCT03613142 is sponsored by Peking University Cancer Hospital & Institute.

What drugs are being tested in NCT03613142?

Interventions in NCT03613142: Double tract anatomosis, Esophagogastrostomy.

What condition does NCT03613142 study?

NCT03613142 studies Gastric Cancer, GastroEsophageal Cancer.

Is NCT03613142 still recruiting?

NCT03613142 is currently status unknown. Last updated 8 November 2018.

Last reviewed 2018-11-08 · How we verify

NCT03613142

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison Between Double Tract Anastomosis and Esophagogastrostomy After Radical Proximal Gastrectomy

Status unknown NA Last updated 8 November 2018

What this trial tests

NA trial testing Double tract anatomosis in Gastric Cancer in 202 participants. Status unknown.

Timeline

1 January 2019

Primary endpoint
30 December 2021

30 December 2021

Quick facts

Lead sponsor	Peking University Cancer Hospital & Institute
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	single
Primary purpose	treatment
Enrollment	202
Start date	1 January 2019
Primary completion	30 December 2021
Estimated completion	30 December 2021

Drugs / interventions tested

Double tract anatomosis
Esophagogastrostomy

Conditions studied

Gastric Cancer — all drugs for Gastric Cancer →
GastroEsophageal Cancer — all drugs for GastroEsophageal Cancer →

Sponsor

Peking University Cancer Hospital & Institute

Who can join

Adults 18 to 80, any sex, with Gastric Cancer or GastroEsophageal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The patients with upper gastric cancer (cT1N0M0) or gastroesophageal adenocarcinoma (diameter less than 4 cm) will be enrolled into this study. Each of these patients will undergo radical proximal gastrectomy and be randomly allocated into one of the two groups, double tract anastomosis group or esophagogastrostomy group. The following data will be collected to compare the difference between the two reconstruction methods: the rate of reflux esophagitis, postoperative quality of life, economic expenditure, the safety of operation, postoperative recovery, postoperative nutrition status and oncological effect. Through the comprehensive analysis, the result of this study will elucidate the best of the reconstruction method after proximal gastrectomy.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Double-tract reconstruction is superior to esophagogastrostomy in controlling reflux esophagitis and enhancing quality of life after proximal gastrectomy: Results from a prospective randomized controlled clinical trial in China.
Zhang Y, Zhang H, Yan Y, Ji K, et al · · 2023 · cited 5× · PMID 38204447 · DOI 10.21147/j.issn.1000-9604.2023.06.09
Double-tract reconstruction is superior in controlling reflux esophagitis and enhancing quality of life after proximal gastrectomy: Results from a prospective randomized controlled clinical trial in China
Zhang Y, Ji X, Yan Y, Ji K, et al · · 2022 · DOI 10.21203/rs.3.rs-1960657/v2

Verify or expand the search:

Other recruiting trials for Gastric Cancer

Currently open trials in the same condition.

NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting

Other Peking University Cancer Hospital & Institute trials

Trials by the same sponsor.

NCT07527806 — Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Im · Phase 2 · not yet recruiting
NCT07529002 — Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors · recruiting
NCT07417241 — SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study · Phase 2 · not yet recruiting
NCT07470203 — Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer · not yet recruiting
NCT07394192 — Short-Course Radiotherapy With Tumor-Draining Lymph Node Preservation Followed by PD-1 Inhibitors in pMMR/MSS Stage II-I · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03613142 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University Cancer Hospital & Institute
Last refreshed: 8 November 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03613142.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing